Generation of an induced pluripotent stem cell line (IGGi002A) from nasal cells of a cystic fibrosis patient homozygous for the G542X-CFTR mutation
Stem Cell Research · 2023
DOI: 10.1016/j.scr.2023.103232 ↗Kurz gefasst
Fachartikel in der Zeitschrift Stem Cell Research, 2023. Verfasst von Michał Dębczyński und 9 weiteren Autor:innen. Beteiligte Einrichtung: II Department of Lung Diseases and Tuberculosis, Medical University of Bialystok, Bialystok, Poland. Hauptthemen laut MEDLINE: Cystic Fibrosis, Induced Pluripotent Stem Cells. Die Arbeit nennt 3 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute, Fondazione per La Ricerca sulla Fibrosi Cistica, Vertex Pharmaceuticals Inc.
Abstract (Originalsprache)
Cystic Fibrosis Transmembrane conductance Regulator (CFTR) is a chloride channel defective in cystic fibrosis (CF). Several CFTR mutations are causative of CF, among which G542X is a nonsense mutation introducing a premature stop codon which prevents CFTR protein synthesis. We generated a new iPSC line from nasal cells carrying G542X homozygous mutation for CFTR: IGGi002A. This cell line has normal female karyotype, express pluripotency markers and could differentiate into three germ layers in vitro. This iPSC line may be used for disease modeling (cell differentiation and organoid formation) and development of personalized treatments by genome editing or pharmacological screening.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- II Department of Lung Diseases and Tuberculosis, Medical University of Bialystok, Bialystok, Poland.
- Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Italy.
- Unit of Medical Genetics, IRCCS Istituto Giannina Gaslini, Genova, Italy.
- Cystic Fibrosis Centre, IRCCS Istituto Giannina Gaslini, Genova, Italy.
- Cystic Fibrosis Unit, Department of Pediatric Subspecialties, Bambino Gesù Children's Hospital, IRCCS-Rome, Italy.
- Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Italy; Unit of Medical Genetics, IRCCS Istituto Giannina Gaslini, Genova, Italy.
Förderung
- Ministero della Salute
- Fondazione per La Ricerca sulla Fibrosi Cistica
- Vertex Pharmaceuticals Inc
Zitieren
APA
Dębczyński, M., Mojsak, D., Tamburro, S., Baldassari, S., Musante, I., Casciaro, R., Ciciriello, F., Zara, F., Scudieri, P., & Gorrieri, G. (2023). Generation of an induced pluripotent stem cell line (IGGi002A) from nasal cells of a cystic fibrosis patient homozygous for the G542X-CFTR mutation. Stem Cell Research. https://doi.org/10.1016/j.scr.2023.103232
Vancouver
Dębczyński M, Mojsak D, Tamburro S, Baldassari S, Musante I, Casciaro R, et al. Generation of an induced pluripotent stem cell line (IGGi002A) from nasal cells of a cystic fibrosis patient homozygous for the G542X-CFTR mutation. Stem Cell Research. 2023. doi:10.1016/j.scr.2023.103232
BibTeX
@article{Dbczyski2023,
author = {Dębczyński, Michał and Mojsak, Damian and Tamburro, Serena and Baldassari, Simona and Musante, Ilaria and Casciaro, Rosaria and Ciciriello, Fabiana and Zara, Federico and Scudieri, Paolo and Gorrieri, Giulia},
title = {Generation of an induced pluripotent stem cell line (IGGi002A) from nasal cells of a cystic fibrosis patient homozygous for the G542X-CFTR mutation},
journal = {Stem Cell Research},
year = {2023},
doi = {10.1016/j.scr.2023.103232}
}
EUVIMED